Literature DB >> 22814660

Ethical considerations in orphan drug approval and use.

A S Kesselheim1.   

Abstract

The Orphan Drug Act seeks to meet a utilitarian goal of advancing therapeutic options for patients with rare diseases. However, data show that orphan drugs are often approved with more limited premarket testing than that carried out for nonorphan drugs and consequently expose patients to more risk and less certain efficacy. Therefore, the ethical principles of justice and beneficence may require attention to informed consent among patients receiving the drugs and greater investment in postmarket surveillance and confirmational testing.

Entities:  

Mesh:

Year:  2012        PMID: 22814660     DOI: 10.1038/clpt.2012.92

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review.

Authors:  Jaroslav Kacetl; Petra Marešová; Raihan Maskuriy; Ali Selamat
Journal:  Risk Manag Healthc Policy       Date:  2020-10-13

Review 2.  Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.

Authors:  Julie Winstone; Shkun Chadda; Stephen Ralston; Peter Sajosi
Journal:  Orphanet J Rare Dis       Date:  2015-10-28       Impact factor: 4.123

Review 3.  New treatments for mitochondrial disease-no time to drop our standards.

Authors:  Gerald Pfeffer; Rita Horvath; Thomas Klopstock; Vamsi K Mootha; Anu Suomalainen; Saskia Koene; Michio Hirano; Massimo Zeviani; Laurence A Bindoff; Patrick Yu-Wai-Man; Michael Hanna; Valerio Carelli; Robert McFarland; Kari Majamaa; Douglas M Turnbull; Jan Smeitink; Patrick F Chinnery
Journal:  Nat Rev Neurol       Date:  2013-07-02       Impact factor: 42.937

Review 4.  Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.

Authors:  Todd Gammie; Christine Y Lu; Zaheer Ud-Din Babar
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.